An Adaptive Dose-Finding Design Based on Both Safety and Immunologic Responses in Cancer Clinical Trials-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

An Adaptive Dose-Finding Design Based on Both Safety and Immunologic Responses in Cancer Clinical Trials

Published:2018-07-03 Issue:3 Volume:10 Page:185-195
ISSN:1946-6315
Container-title:Statistics in Biopharmaceutical Research
language:en
Short-container-title:Statistics in Biopharmaceutical Research

Author:

Chiuzan Cody¹,Garrett-Mayer Elizabeth²,Nishimura Michael I.³

Affiliation:

1. Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY

2. Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC

3. Department of Surgery, Cardinal Bernardin Cancer Center, Loyola University, Chicago, Maywood, IL

Publisher

Informa UK Limited

Subject

Pharmaceutical Science,Statistics and Probability

Link

https://www.tandfonline.com/doi/pdf/10.1080/19466315.2018.1462727

Reference33 articles.

1. Likelihood methods for measuring statistical evidence

2. The bivariate continual reassessment method

3. Sequential Designs for Phase I Clinical Trials with Late-Onset Toxicities

4. A likelihood-based approach for computing the operating characteristics of the 3+3 phase I clinical trial design with extensions to other A+B designs

5. Evaluation of Statistical Designs in Phase I Expansion Cohorts: The Dana-Farber/Harvard Cancer Center Experience

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Randomized Phase I Trials — One Size Fits All?;NEJM Evidence;2023-11-28

2. Rejoinder: Improving the performance of Bayesian logistic regression model with overdose control in oncology dose‐finding studies;Statistics in Medicine;2022-11-17

3. Clinical Strategies for Enhancing the Efficacy of CAR T-Cell Therapy for Hematological Malignancies;Cancers;2022-09-14

4. A Bayesian phase I/II platform design for co‐developing drug combination therapies for multiple indications;Statistics in Medicine;2021-11-03

5. Seamless phase I/II design for novel anticancer agents with competing disease progression;Statistics in Medicine;2021-07-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3